Comparing Efficacy & Safety of TNX-1300 to Placebo with UC for Treatment of Acute Cocaine Intoxication in ED Subjects (CATALYST)

Tonix Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Cocaine Intoxication; Cocaine Toxicity; Cocaine Use; Cocaine Abuse; Cocaine Adverse Reaction

Treatments: Drug: Placebo (Injection); Drug: TNX-1300 (Injection)

Study type: Interventional

Funder types: Industry; Other; NIH

Identifiers

NCT06045793

5U01DA056245 (U.S. NIH Grant/Contract)

TNX-CE-CI202

Details and patient eligibility

About

This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department setting.

Enrollment: 36 estimated patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject is male or female and is 18-64 years of age.

• Subject has the capacity to provide voluntary written informed consent. In cases in which the investigator is unclear if the subject has the capacity to consent, a determination regarding capacity must be made by a psychiatrist trained in assessment of capacity to consent to research in order for the subject to be eligible.

• At Screening, subject presents with cardiac symptoms while intoxicated with cocaine, inclusive of elevated systolic or diastolic BP, as defined below, with or without behavioral symptoms:

  • Systolic BP >140 mmHg, or
  • Diastolic BP >90 mmHg Note: subjects with a QT interval corrected for heart rate (QTc) >500 msec may be eligible for study participation, based on investigator judgment.

• At Screening and Baseline assessments, subject must have a SIS total score of ≥4

• At Baseline, subject has a CGI-S score ≥3.

• Subject has a positive urine drug screen test at Pre-screening to confirm cocaine use and detect polysubstance abuse (subject may test positive for cannabinoids and/or opioids and remain eligible; subject may test positive for alcohol by breathalyzer and remain eligible).

• Subject must be willing to practice the following:

  • If female, practice one of the following methods of birth control throughout the study and for 28 days after study drug administration:
  • Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of one full cycle (based on the patient's usual menstrual cycle period) before study drug administration;
  • Intrauterine device;
  • Bilateral tubal ligation
  • Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jelly or cream);
  • If male, practice double-barrier method throughout the study and for 28 days after study drug administration, if female partner is not following birth control methods a-c mentioned above

• Subject is a suitable candidate for investigational treatment based on the opinion of the investigator.

Exclusion criteria

• Subject who has been admitted to the ED involuntarily.
• Subject who participated in this clinical study previously.
• Subject has a score of 3 on the systolic and/or diastolic BP SIS components, a "mental state" or "orientation" SIS component score of ≥2, or an "orientation" SIS component score of ≥1 and the subject is not oriented to either person or place (i.e., only disorientation to time is allowed).
• Subject who, at Screening, expresses C-SSRS suicidal ideation of Type 4 or 5 in the prior week or any C-SSRS suicidal behavior in the prior week.
• Subject tests positive for stimulant drugs of abuse other than cocaine, including methylphenidate, 3,4-methylenedioxymethamphetamine, methamphetamine, or other amphetamines at Screening.
• Subject has a clinically significant untreated cardiac condition, such as prior myocardial infarction, current ischemia assessed by ECG-based criteria, aortic dissection, ventricular fibrillation, Torsade de pointes, ventricular tachycardia, cardiomyopathy, pulmonary edema, cardiac arrest, significant conduction disturbance (e.g., greater than first degree heart block), QRS interval >120 msec, or severe or life-threatening hypertension. Untreated hypertension may be allowed if not considered severe or life-threatening. Note: hypertension will be considered severe or life-threatening if systolic BP is >200 mmHg and/or diastolic BP is >130 mmHg.
• Subject incurred or is likely to incur a myocardial infarction or other life-threatening severe event or has acute ECG changes indicative of acute coronary syndrome according to investigator judgment. Such changes may include new, transient, or dynamic ST-segment elevation, ST-depression, or significant Q waves. Based on investigator judgement, T-wave inversion and T-wave flattening may also be considered in the risk assessment for acute coronary syndrome.
• Subject has a heart rate ≥180 bpm, atrial fibrillation, greater than first degree heart block, or chest pain with ECG-based evidence of ischemia.
• Subject has a clinically significant or unstable medical illness, condition, or disorder that can compromise subject safety or adversely affect the evaluation of clinical outcome parameters.
• Subject has a clinical history of anaphylaxis, severe asthma, hypersensitivity, or angioedema.
• Subject requires physical restraints due to physiological and/or behavioral symptoms.
• Subject receives anti-hypertensive medication(s) in the ED prior to study enrollment.
• Subject is pregnant or breastfeeding.
• Participation in another investigational drug study (current or within 30 days of Screening) or previous participation in a study of TNX-1300.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Parallel Assignment

Masking: Single Blind

---

36 participants in 2 patient groups, including a placebo group

TNX-1300

Experimental group

Description:

A single IV 200 mg injection of TNX-1300

Treatment:

Drug: TNX-1300 (Injection)

Placebo

Placebo Comparator group

Description:

A single IV injection of placebo with UC

Treatment:

Drug: Placebo (Injection)